help button home button The Oncologist
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow eLetters: Submit a response to this article
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Talcott, J. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Talcott, J. A.
The Oncologist, Vol. 2, No. 6, 365–373, December 1997
© 1997 AlphaMed Press

Outpatient Management of Febrile Neutropenia: Should We Change the Standard of Care?

James A. Talcott

Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA

Correspondence: James A. Talcott, M.D., S.M., Center for Outcomes Research, Massachusetts General Hospital, B75 230, 55 Fruit Street, Boston, Massachusetts 02114, USA. Telephone 617-724-5451; Fax: 617-724-5457; e-mail: talcott{at}dfci.harvard.edu

The syndrome of fever and neutropenia is an iatrogenic complication of cytotoxic therapy for cancer. Because febrile neutropenia is associated with serious infection, patients with the syndrome are treated emergently with broad-spectrum, high-dose antibiotics. Recently, a differentiated approach to febrile neutropenia has been explored, based on assessment of risk. Prediction rules to identify low-risk patients were developed, and outpatient management of low-risk patients has been explored. Based on pilot studies and early randomized trials, some have called for a new standard of outpatient care. This article describes the scientific rationale for the current standard of care for febrile neutropenia; reviews the risk assessment studies; discusses the issues of safety, quality of life, and shifting of economic burdens arising when outpatient care is substituted for inpatient care—a change in practice patterns sweeping through acute care medicine with little scrutiny; and critically reviews the published trials of outpatient treatment of febrile neutropenia.

Key Words. Fever • Neutropenia • Risk assessment • Practice guidelines • Outpatient care







HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS


Copyright © 1997 by AlphaMed Press.